MedTrace Logo

Artificial Intelligence Prediction Tool in Non-muscle Invasive Bladder Cancer (NMIBC)

NCT05825950 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 600

Last updated 2025-08-17

No results posted yet for this study

Summary

This is a multi-center study and the aim is to develop and validate an Artificial Intelligence (AI) -based histologic analysis tool to predict responsiveness to intravesical Bacillus Calmette-Guérin (BCG) and intravesical chemotherapy in intermediate and high-risk non-muscle invasive bladder cancer patients.

Conditions

  • Non-muscle-invasive Bladder Cancer

Sponsors & Collaborators

  • Valar Labs

    collaborator UNKNOWN

  • University of Texas Southwestern Medical Center

    lead OTHER

Principal Investigators

  • Yair Lotan, MD · UT Southwestern Medical Center

Eligibility

Min Age
18 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-25
Primary Completion
2026-09-30
Completion
2026-09-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05825950 on ClinicalTrials.gov